Sunday 18 October 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE
Insiders bought in the last twelve months.
18.71
0.84
−4.30%
Follow BRVE
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+1 more quarter Free account |
— | 17.03 | 8.11 | 13.63 |
Net Debt/EBITDA |
0.00 | 0.00 | 5.34 | 7.72 | |
Debt/Assets |
— | 0.00% | 0.36% | 0.16% | |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | — | 0.36 | 0.91 | |
Capex/Depreciation |
— | — | (18.00) | 2.67 | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
— | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
0.00 | — | (0.76) | (2.29) | |
Cash per Share |
0.00 | 0.00 | 11.74 | 16.59 | |
Shareholders Equity per Share |
0.00 | 0.00 | (11.42) | (12.96) | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | (11.42) | (12.96) | |
Free Cash Flow |
0.00 | — | (5.22) | (16.94) | |
Working Capital |
— | 84.04 | 71.07 | 114.39 | |
Capital Expenditures |
— | — | (0.04) | 0.01 | |
Net Current Asset Value |
— | (65.94) | (79.20) | (99.42) | |
| Other line items | |||||
Quick Ratio |
— | 17.01 | 8.06 | 13.56 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | — | (0.76) | (2.29) | |
Capex per Share |
0.00 | — | (0.01) | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 1 Oct 2026